Graves' Orbitopathy Drug Development Pipeline: 2025 Market Intelligence 

DelveInsight's comprehensive 2025 analysis of the Graves' Orbitopathy pipeline delivers extensive intelligence on over 8 companies and more than 8 investigational therapies currently advancing through development. This detailed examination encompasses drug candidate profiles across all developmental phases, from preclinical research through clinical trials. The assessment evaluates therapeutic candidates by product classification, developmental phase, administration method, and molecule type, while also documenting discontinued programs in this therapeutic area.

Curious about the latest updates in the Graves' Orbitopathy Pipeline? Click here to explore the therapies and trials making headlines @ Graves' Orbitopathy Pipeline Outlook Report

Key Highlights from the Pipeline Analysis

• On 03 October 2025, Innovent Biologics (Suzhou) Co. Ltd revealed a phase II investigation evaluating IBI311 efficacy and safety in subjects diagnosed with inactive or active thyroid eye disease. Approximately 36 subjects meeting the study eligibility criteria will be randomly assigned to the 3-10 mg group, 3-20 mg group, 10 mg group, or 20 mg group on day 1 in a 1:1:2:2 ratio.

• The current landscape shows a dynamic field with over 8 companies actively advancing more than 8 therapeutic candidates for Graves' Orbitopathy management.

• Key pharmaceutical developers include Astellas, Jiangsu Hengrui Medicine, Novartis and others.

• Notable investigational therapies comprise Teprotumumab, RVT-1401, VRDN-003, Veligrotug (VRDN-001), Batoclimab, IBI311 (20 mg), lonigutamab, Satralizumab, TEPEZZA, LASN01, and additional candidates.

Want to know which companies are leading innovation in Graves' Orbitopathy? Dive into the full pipeline insights @ Graves' Orbitopathy Clinical Trials Assessment

Understanding Graves' Orbitopathy

Graves orbitopathy (Graves eye disease or Graves ophthalmopathy) represents a constellation of signs and symptoms related to the orbit and surrounding tissues in patients diagnosed with Graves disease. It can also sporadically manifest in patients who are euthyroid or even hypothyroid as a result of chronic thyroiditis. It represents an autoimmune process affecting retro-ocular tissues. In its severe manifestation, it can be sight-threatening; thus, prompt evaluation and timely referral and management become of paramount importance. Graves orbitopathy occurs in patients with Graves disease and constitutes an autoimmune disease of retro-ocular tissue.

Featured Investigational Therapies

Linsitinib: Astellas Linsitinib, which was in-licensed from Astellas Pharma to Sling Therapeutics, is engineered to inhibit the insulin-like growth factor I receptor (IGF-1R). Dysfunction in the IGF-1R signaling pathway leads to a prevalence of thyroid-stimulating hormone receptor autoantibodies (TSHR-Abs) that drive excess fibrous tissue growth in TED. Independent data from a model of TED in patient fibroblast cells suggest that linsitinib demonstrates at least equivalent potency as currently available treatment. The U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for linsitinib for TED treatment. This compound is currently in Phase II/III clinical trial evaluation for treating Graves Orbitopathy.

SHR 1314: Jiangsu Hengrui Medicine Vunakizumab (SHR 1314) is being developed by Jiangsu Hengrui Medicine for treating psoriasis and other autoimmune diseases. This compound is currently in Phase II clinical trial evaluation for treating Active Moderate to Severe Graves' Orbitopathy.

If you're tracking ongoing Graves' Orbitopathy Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Graves' Orbitopathy Treatment Drugs

Report Coverage and Analysis

This comprehensive pipeline report delivers intelligence on:

• Detailed profiles of pharmaceutical companies developing Graves' Orbitopathy therapeutics, including aggregate therapy portfolios from each organization.

• Assessment of therapeutic candidates classified by early-stage, mid-stage, and late-stage development phases.

• Active and inactive (dormant or discontinued) pipeline programs across participating companies.

• Categorization of investigational drugs by developmental stage, delivery route, target receptor, treatment approach (monotherapy or combination), mechanism of action, and molecular classification.

• In-depth examination of partnerships (industry collaborations and academic alliances), licensing arrangements, and funding details relevant to future market advancement.

Featured Companies

Astellas, Jiangsu Hengrui Medicine, Novartis and others.

Route of Administration Categories

Pipeline products are organized by delivery method:

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Molecular Type Classifications

Investigational products are categorized by molecular structure:

• Oligonucleotide

• Peptide

• Small molecule

From emerging drug candidates to competitive intelligence, the Graves' Orbitopathy Pipeline Report covers it all - check it out now @ Graves' Orbitopathy Market Drivers and Barriers, and Future Perspectives

Report Scope

• Geographic Coverage: Global

• Featured Companies: Astellas, Jiangsu Hengrui Medicine, Novartis and others

• Pipeline Therapies: Teprotumumab, RVT-1401, VRDN-003, Veligrotug (VRDN-001), Batoclimab, IBI311 (20 mg), lonigutamab, Satralizumab, TEPEZZA, LASN01, and others

• Product Type Assessment: Monotherapy, Combination therapy, Mono/Combination approaches

• Clinical Stage Assessment: Discovery, Preclinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Graves' Orbitopathy Treatment landscape in this detailed analysis @ Graves' Orbitopathy Emerging Drugs and Major Players

Report Structure

1. Introduction

2. Executive Summary

3. Graves' Orbitopathy: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Graves' Orbitopathy- DelveInsight's Analytical Perspective

7. Late Stage Products (Phase II/III)

8. Linsitinib: Astellas

9. Drug profiles in the detailed report.....

10. Mid Stage Products (Phase II)

11. SHR 1314: Jiangsu Hengrui Medicine

12. Drug profiles in the detailed report.....

13. Early Stage Products (Phase I)

14. Drug name: Company name

15. Drug profiles in the detailed report.....

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report.....

19. Inactive Products

20. Graves' Orbitopathy Key Companies

21. Graves' Orbitopathy Key Products

22. Graves' Orbitopathy- Unmet Needs

23. Graves' Orbitopathy- Market Drivers and Barriers

24. Graves' Orbitopathy- Future Perspectives and Conclusion

25. Graves' Orbitopathy Analyst Views

26. Graves' Orbitopathy Key Companies

27. Appendix

About DelveInsight

DelveInsight operates as a premier healthcare-focused market research and consulting organization, delivering high-caliber market intelligence and analytical insights that empower informed business decision-making. Supported by seasoned industry specialists and comprehensive expertise in life sciences and healthcare domains, the firm provides tailored research solutions and strategic insights to a global client base. Engage with our team to access premium-quality, precise, and current intelligence that positions you ahead of market developments.

Contact Us 

Kanishk

kkumar@delveinsight.com